Fig. 5: Relative abundance of TME cell types in pre- and on-treatment samples of long-term and short-term survivors. | Communications Medicine

Fig. 5: Relative abundance of TME cell types in pre- and on-treatment samples of long-term and short-term survivors.

From: Progression-free survival for unresectable non-metastatic locally advanced pancreatic cancer after surgical microwave ablation plus durvalumab and tremelimumab: phase-2 non-randomized prospective clinical trial

Fig. 5

Proportions were calculated for main cell types (a) and immune cell subtypes, including T cells (b), B cells (c) and myeloid cells (d). STS short-term survivors, LTS long-term survivors.

Back to article page